Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.

Completed · Phase 1/Phase 2

Conditions studied: Alzheimer Disease

In brief

Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.

Key facts

Study ID

NCT00380302

Run by

Sanofi

People needed

162

Starts

2006-09-01

Expected to finish

2007-07-01

Last updated by the study team

2008-12-19

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The diagnosis of Alzheimer's disease
• Recent brain image(Computerized Axial Tomographic Scan -CAT scan or Magnetic Resonance Imaging - MRI)
• Mild to moderate range of disease; not too severe

You may not qualify if…

• Severe or unstable medical diseases
• Neurological disorder other than Alzheimer's disease
• Depression that is not well controlled
• Treatment with memantine
• Inpatient in a total care facility (e.g.: Nursing home)
• Lack of reliable caregiver

Where it is running

• Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States
• Sanofi-Aventis Administrative Office — Paris, France
• Sanofi-Aventis Administrative Office — Milan, Italy
• Sanofi-Aventis Administrative Office — Gouda, Netherlands
• Sanofi-Aventis Administrative Office — Bromma, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.